Ambrose Kristen, SVP & Chief Accounting Officer, has demonstrated a consistent pattern of selling shares in Vertex Pharmaceuticals (VRTX) over the past two years, with no recorded purchases. According to SEC Form 4 filings, Kristen executed 30 transactions totaling over $8.14 million in sales, with no offsetting buys. The most recent activity, concentrated in February 2026, included multiple sales ranging from $108,456 to $762,089, with the largest single transaction occurring on February 17, 2026. Earlier transactions followed a similar trend, including a $425,160 sale on February 25, 2025, and a $375,893 sale on February 26, 2024.
The filings also show periodic awards (coded "A") and dispositions to satisfy tax obligations (coded "F"), but the overwhelming majority of activity involves outright sales (coded "S"). Notably, the transactions cluster around mid-to-late February annually, suggesting a possible structured selling plan tied to equity compensation vesting. The absence of buying activity and the repeated liquidation of shares indicate a clear disposition bias toward reducing exposure to VRTX stock. While the sales represent a significant divestment, the consistency in timing and method points to a systematic approach rather than discretionary trading.
AI-assisted summary